Phase 2 N=109 Effect of PBT2 in Patients With Early to Mid Stage Huntington Disease
Huntington Disease
Primary: Safety and Tolerability of PBT2 in Patients With HD — 32; 30; 28 participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=134 Open-label Extension Study of Pridopidine (ACR16) in the Symptomatic Treatment of Huntington Disease
Huntington Disease
Primary: Number of Patients With at Least One Adverse Event — 119 Participants
Phase 2 N=272 Randomized, Placebo Controlled Study Of The Efficacy And Safety Of PF-02545920 In Subjects With Huntington's Disease
Huntington's Disease
Primary: Change From Baseline in the Total Motor Score (TMS) Assessment of the Unified Huntington Disease Rating Scale (UHDRS) After 26 Weeks of Treatment. — 0.4; -0.8; -1.4…
Phase 2 N=139 Efficacy and Safety on SOM3355 in Huntington's Disease Chorea
Huntington Chorea
Primary: Change in Total Maximal Chorea (TMC) Score of the UHDRS® for Subjects Not Taking Neuroleptics During the Trial (mITT - N=122) — -2.19; -2.42; -3.46 units on a scale…
Phase 4 N=50 Study of Memantine to Treat Huntington's Disease
Huntington's Disease
Primary: Change in the Hopkins Verbal Learning Test - Revised for Delayed Recall (HVLT-R-delayed Recall)
Phase 3 N=90 First Time Use of SD-809 in Huntington Disease
Chorea
Primary: Change From Baseline (Average of Screening and Day 0) in the Average TMC Scores From Weeks 9 & 12 — -4.42; -1.93 Units on a scale — p=<0.0001
N/A N=11 Impact of Xenazine(Tetrabenazine)on Gait and Functional Activity in Individuals With Huntington's Disease
Huntington's Disease
Primary: Tinetti Mobility Test Score — 19.91; 17.09 Total Tinetti Mobility Test Score (TMT)
Phase 3 N=128 Efficacy, Safety, and Tolerability of Valbenazine for the Treatment of Chorea Associated With Huntington Disease
Chorea, Huntington
Primary: Change From Screening Period Baseline to Maintenance Period in the Unified Huntington's Disease Rating Scale (UHDRS) Total Maximal Chorea (TMC) Score. — -4.60; -1.44…
N/A N=42 Examination of Quantitative Electroencephalographic (QEEG) Biomarkers in Huntington's Disease
Huntington's Disease
Primary: Quantitative Electroencephalography Absolute Delta Power. — 43.45; 10.11 microvolts squared — p=<0.0000001
Phase 1 N=95 Study to Measure Cerebrospinal Fluid Mutant Huntingtin Protein in Participants With Early Manifest Stage I or Stage II Huntington's Disease
Huntington's Disease
Primary: Change From Baseline in the Following Clinical Endpoints at 3, 9, and 15 Months: cUHDRS, TFC, TMS, SDMT, SWR Test and IS — 0.19; -0.12; -0.76; -0.24 Scores on a scale
Phase 2 N=47 Study of WVE-003 in Patients With Huntington's Disease
Huntington Disease
Primary: Safety: Proportion of Patients With Treatment Emergent Adverse Events (TEAEs) Related to Study Drug — 2; 1; 3; 3 Participants
Phase 2 N=227 A Study of Pridopidine (ACR16) for the Treatment of Participants With Huntington's Disease
Huntington Disease
Primary: Change From Baseline in Modified Motor Score (mMS) (Sum of Score of Items 4-10 and 13-15 of the UHDRS Motor Assessments) at Week 12 — -1.40; -1.30; -2.49; -2.32 units on…
N/A N=24 The Effect of Video Game Exercise on Dynamic Balance and Gait in Individuals With Huntington's Disease
Huntington's Disease
Primary: Gait Parameters — 1.289; 1.292 meters per second
Phase 2 N=6 Risperidone for the Treatment of Huntington's Disease Involuntary Movements
Huntington Disease · Chorea
Primary: Change From Baseline in Mean Unified Huntington's Disease (HD) Rating Scale Total Maximal Chorea (UHDRS TMC) Score — -2.4 score on a scale — p=0.27
Phase 2 N=46 Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ISIS 443139 in Participants With Early Manifest Huntington's Disease
Huntington's Disease
Primary: Number of Participants With Treatment-related Adverse Events (TEAEs) — 12; 3; 6; 6 Participants
Phase 2 N=37 Study Evaluating The Safety, Tolerability And Brain Function Of 2 Doses Of PF-0254920 In Subjects With Early Huntington's Disease
Huntington's Disease
Primary: Number of Participants With Treatment-Emergent Adverse Events (AEs) or Serious Adverse Events (SAEs) — 18; 14; 1; 1 participants
Phase 2 N=20 Atomoxetine and Huntington's Disease
Huntington Disease · Chorea
Primary: Conners' Adult Attention Rating Scale (CAARS) — -2.88; -2.24 units on a scale — p=0.63
Phase 3 N=437 A Study of Treatment With Pridopidine (ACR16) in Participants With Huntington's Disease
Huntington's Disease
Primary: Change From Baseline in Modified Motor Score (mMS) (Sum of Score of Items 4-10 and 13-15 of the Unified Huntington's Disease Rating Scale [UHDRS] Motor Assessments) at…
Phase 2 N=159 A Study to Evaluate the Safety and Efficacy of PTC518 in Participants With Huntington's Disease (HD)
Huntington Disease
Primary: Number of Participants With Treatment-emergent Adverse Events (TEAEs) — 46; 43; 49 Participants
Phase 2 N=10 Creatine Safety & Tolerability in Huntington's Disease
Huntington's Disease (HD)
Primary: Tolerability — 5 Participants
Phase 3 N=114 Pilot Study of Minocycline in Huntington's Disease
Huntington Disease
Primary: Change From Baseline to Month 18 in the Total Functional Capacity (TFC) Scale [LOCF Imputation Method] — 1.55; 1.15 units on a scale
Phase 3 N=119 Alternatives for Reducing Chorea in Huntington Disease
Chorea Associated With Huntington Disease
Primary: Number of Participants With Treatment-Emergent Adverse Events (TEAEs), Serious TEAEs, Severe TEAEs, Drug-Related TEAEs, and TEAEs Leading to Withdrawal During Entire…
Phase 2 N=408 A Phase 2, to Evaluating the Safety and Efficacy of Pridopidine Vs Placebo for Symptomatic Treatment in Patients With Huntington's Disease
Huntington's Disease
Primary: Change From Baseline in Unified Huntington's Disease Rating Scale-Total Motor Score (UHDRS-TMS) at Week 26 — -4.79; -3.37; -3.09; -4.13 score on a scale — p=0.3202
Phase 2 N=69 28-Day Study of SAGE-718 on Functioning Capacity in Participants With Huntington's Disease
Huntington Disease
Primary: Difference in Huntington's Disease Cognitive Assessment Battery (HD-CAB) Composite Score Between Participants With HD vs HP at Baseline — -3.3657; 0.0000 Z score…
Phase 3 N=899 A Study to Evaluate the Efficacy and Safety of Intrathecally Administered RO7234292 (RG6042) in Participants With Manifest Huntington's Disease
Huntingtons Disease
Primary: Change From Baseline in the Composite Unified Huntington's Disease Rating Scale (cUHDRS) Score-Z Score — 0.103; -0.367; -0.139; -1.173 Scores on a Scale
Phase 3 N=499 PRidopidine's Outcome On Function in Huntington Disease, PROOF- HD
Huntington Disease
Primary: Change From Baseline in the Unified Huntington Disease Rating Scale-Total Functional Capacity (UHDRS-TFC) Score (mITT) — -1.18; -0.95 score on a scale — p=0.1670
Phase 4 N=2 Effect of Tetrabenazine on Stroop Interference in HD
Huntington Disease
Primary: Change in Stroop Interference Score — -1.97; -1 score on a scale
Phase 2 N=10 Proof of Concept of an Anaplerotic Study Using Brain Phosphorus Magnetic Resonance Spectroscopy in Huntington Disease
Huntington Disease
Primary: Ratio of Inorganic Phosphate (Pi) Over Phosphocreatine (PCr): Pi/PCr — 0.44; 0.43; 0.44; 0.42 ratio
Phase 2 N=10 Safety and Efficacy of Fenofibrate as a Treatment for Huntington's Disease
Huntington Disease
Primary: Change in PGC-1alpha RNA Expression — -0.02190716; 0.3160562; 0.07414876; 0.4800263 Log 2 fold change
Phase 2 N=352 A Clinical Study in Participants With Huntington's Disease (HD) to Assess Efficacy and Safety of Three Oral Doses of Laquinimod
Huntington's Disease
Primary: Change From Baseline in UHDRS-TMS at Week 52 — 1.3; 1.4; 2.0; 11.0 units on a scale — p=0.4853